Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Study Details
Study Description
Brief Summary
At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk.
When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Choosing to participate in an early patient access program is an important personal decision. Talk with your doctor and family members or friends about deciding to participate in an early patient access program.
To learn more about early patient access programs, your doctor may contact BMS using the information provided below.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Specific eligibility criteria must be met for access outside of a clinical trial.
These inclusion criteria include:
-
The illness must be serious or life threatening
-
There are no other viable options (including approved products or active clinical trials)
-
There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time
-
Other defined inclusion/exclusion criteria could be applicable.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Bristol-Myers Squibb
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- EAP-01-CA204